Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial
Outlook Therapeutics faces setback as its wet AMD therapy, Lytenava, failed to meet a key endpoint in Phase III NORSE EIGHT trial. Despite this, the company plans to resubmit for US approval in Q1 2025 and is exploring international markets.